Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer.

abstract：:Esophageal carcinoma (EC) is a lethal disease with high morbidity and mortality worldwide, and the incidence has been increasing in recent years. Although the diagnosis and treatment of EC have improved considerably, EC has rapidly progressed in the clinical setting and has a poor prognosis for its metastasis and recu...

journal_title：OncoTargets and therapy

authors： Qian X,Tan C,Wang F,Yang B,Ge Y,Guan Z,Cai J

更新日期：2016-04-19 00:00:00

abstract：:Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic thera...

journal_title：OncoTargets and therapy

authors： Zhao X,Hu GF,Shi YF,Xu W

更新日期：2019-12-24 00:00:00

abstract：Purpose:As a novel type of non-coding RNAs, circRNAs were found to play important roles in cancer progression. In this study, we aim to investigate genome-wide circRNAs expression and potential functions in glioma to find new therapeutic targets for glioma treatment. Patients and Methods:A total of 92 pairs of glioma ...

journal_title：OncoTargets and therapy

authors： Lyu X,Zhou L,Fan F,Dong Z

更新日期：2020-04-01 00:00:00

abstract：Background:Abnormal miR-27a-3p expression has been frequently reported in several types of human cancer and contributes to tumor progression. However, the role and potential molecular mechanism of miR-27a-3p in the progression of pancreatic carcinoma have not been clarified. Materials and methods:The expression of miR...

journal_title：OncoTargets and therapy

authors： Rao X,Wan L,Jie Z,Zhu X,Yin J,Cao H

更新日期：2019-12-19 00:00:00

abstract：:In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. A...

journal_title：OncoTargets and therapy

authors： Fang SC,Zhang HT,Zhang YM,Xie WP

更新日期：2017-01-18 00:00:00

abstract：:The view that B lymphocytes are pathogenic in diverse pathological settings is supported by the efficacy of B-cell-ablative therapy in lymphoproliferative disorders, autoimmune diseases and graft rejection. Anti-B-cell antibodies (Abs) directed against CD20 have therefore been generated, and of these, rituximab was th...

journal_title：OncoTargets and therapy

authors： Hammadi M,Pers JO,Berthou C,Youinou P,Bordron A

更新日期：2010-06-24 00:00:00

abstract：Purpose:Programmed death ligand 1 (PD-L1) is widely used for predicting immune checkpoint inhibitors but has a limited effect on predicting clinical response. The aim of this study was to examine the prognostic value and PD-1 inhibitor therapeutic efficiency of SNX20 in lung adenocarcinoma. Methods:We evaluated the mR...

journal_title：OncoTargets and therapy

authors： Fan L,Li L,Huang C,Huang S,Deng J,Xiong J

更新日期：2020-10-09 00:00:00

abstract：BACKGROUND:The aim of this study was to examine the patterns of expression of epithelial-mesenchymal transition (EMT)-related proteins in intrahepatic cholangiocarcinoma. The clinicopathological and prognostic value of these markers was also evaluated. METHODS:We detected the expression status of three EMT-related pro...

journal_title：OncoTargets and therapy

authors： Yao X,Wang X,Wang Z,Dai L,Zhang G,Yan Q,Zhou W

更新日期：2012-01-01 00:00:00

abstract：:Pleiotropy in biological systems and their targeting allows many pharmaceuticals to be used for multiple therapeutic purposes. Fully exploiting the therapeutic properties of drugs that are already marketed would be highly advantageous. This is especially the case in the field of oncology, where the ineffectiveness of ...

journal_title：OncoTargets and therapy

authors： Papanagnou P,Papadopoulos GE,Stivarou T,Pappas A

更新日期：2018-12-31 00:00:00

abstract：PURPOSE:Although numerous studies have demonstrated associations between the preoperative neutrophil-to-lymphocyte ratio (NLR) and long-term outcomes in patients with non-small cell lung cancer (NSCLC), the prognostic significance of postoperative NLR and change in NLR (ΔNLR) is unknown for patients who underwent compl...

journal_title：OncoTargets and therapy

authors： Jin F,Han A,Shi F,Kong L,Yu J

更新日期：2016-10-21 00:00:00

abstract：:Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option. The management of locally advanced (unresectable) pancreatic cancer is controversial; however, treatment with either chemotherapy or c...

journal_title：OncoTargets and therapy

authors： Hong JC,Czito BG,Willett CG,Palta M

更新日期：2016-10-31 00:00:00

abstract：Purpose:Tumor drug resistance limits the response to chemotherapy. Interestingly, sequential combination therapy enhances the anticancer efficacy of drugs like cisplatin (CDDP) via synergistic effects. We assayed the synergistic effects of combined photodynamic therapy programmed death receptor-ligand 1 (PDT) and chemo...

journal_title：OncoTargets and therapy

authors： Xue K,Wang YN,Zhao X,Zhang HX,Yu D,Jin CS

更新日期：2019-07-10 00:00:00

abstract：Background:Erlotinib is a commonly used molecular-targeted drug for the treatment of tongue cancer. However, the development of acquired resistance to erlotinib hampers its therapeutic use. Materials and methods:To analyze the erlotinib resistance, long-term and short term survival assay were used to compare the resis...

journal_title：OncoTargets and therapy

authors： Huang K,Liu D

更新日期：2018-09-05 00:00:00

abstract：:Forkhead box protein O1 (FOXO1) is a multifunctional transcription factor of the forkhead family. It may function as a tumor suppressor through its ability to regulate cellular events, including cell proliferation, apoptosis, and cell cycle control. As reported, FOXO1 is downregulated in papillary thyroid carcinoma (P...

journal_title：OncoTargets and therapy

authors： Song HM,Song JL,Li DF,Hua KY,Zhao BK,Fang L

更新日期：2015-12-01 00:00:00

abstract：Background:Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) are two of the main treatment techniques for cervical cancer. Whether either technique significantly reduces irradiated volumes of organs at risk (OARs) remains controversial. The aim of this study was to explore which o...

journal_title：OncoTargets and therapy

authors： Bai W,Kou C,Yu W,Li Y,Hua W,Yu L,Wang J

更新日期：2018-10-18 00:00:00

abstract：Background:Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients' outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeutic window may exist ...

journal_title：OncoTargets and therapy

authors： Fleisher B,Ait-Oudhia S

更新日期：2017-12-27 00:00:00

abstract：BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via proteinase-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase phosphorylat...

journal_title：OncoTargets and therapy

authors： Ammendola M,Sacco R,Sammarco G,Piardi T,Zuccalà V,Patruno R,Zullo A,Zizzo N,Nardo B,Marech I,Crovace A,Gadaleta CD,Pessaux P,Ranieri G

更新日期：2016-07-21 00:00:00

abstract：BACKGROUND:Recurrent laryngeal nerve (RLN) invasion in papillary thyroid carcinoma (PTC) is one of the main predictors of poor prognosis. The present study investigated the risk factors for RLN invasion in PTC patients. METHODS:A total of 3,236 patients who received thyroidectomy due to PTC in Thyroid and Parathyroid ...

journal_title：OncoTargets and therapy

authors： Chen W,Lei J,You J,Lei Y,Li Z,Gong R,Tang H,Zhu J

更新日期：2017-09-11 00:00:00

abstract：BACKGROUND:To evaluate the benefit of second-line chemotherapy with platinum-based treatment in patients with recurrent small cell lung cancer (SCLC). PATIENTS AND METHODS:A total of 535 patients continued with follow-up or best supportive care if needed, and 229 patients who progressed after the completion of first-l...

journal_title：OncoTargets and therapy

authors： Zarogoulidis K,Boutsikou E,Zarogoulidis P,Darwiche K,Freitag L,Porpodis K,Latsios D,Kontakiotis T,Huang H,Li Q,Hohenforst-Schmidt W,Kipourou M,Turner JF,Spyratos D

更新日期：2013-10-22 00:00:00

abstract：:Despite advances in the treatment of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently observed. Recently, immunotherapies, in particular, monoclonal antibodies, have become important treatment options in anticancer therapies. Elotuzumab is a humanized monoclonal antibody to s...

journal_title：OncoTargets and therapy

authors： Weisel K

更新日期：2016-10-05 00:00:00

abstract：Background:miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied. Objective:This study aimed to analyze the expression profile of miR-486-5p in tumor ti...

journal_title：OncoTargets and therapy

authors： Zheng X,Xu K,Zhu L,Mao M,Zhang F,Cui L

更新日期：2020-05-28 00:00:00

abstract：:Purpose: NSD3 (WHSC1L1) is a protein lysine methyltransferase that is recurrently amplified (8p11.23) in several cancer types, and its upregulation is involved in tumor cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT). We aimed to evaluate its potential function as an oncogenic force in colo...

journal_title：OncoTargets and therapy

authors： Yi L,Yi L,Liu Q,Li C

更新日期：2019-05-21 00:00:00

abstract：Background and aims:Studies show that the long non-coding RNA, SBF2-AS1, plays a critical role in cancer progression, but the role of SBF2-AS1 in gastric cancer has not been reported. Therefore, this study aimed to elucidate the mechanism of SBF2-AS1 in gastric cancer (GC). Methods:A meta-analysis, based on the gene e...

journal_title：OncoTargets and therapy

authors： Liang C,Yue C,Liang C,Ge H,Wei Z,Li G,Wu J,Huang H,Guo J

更新日期：2019-10-30 00:00:00

abstract：:ISL1 plays a key role in several cancers, including pheochromocytoma, gastrointestinal, pancreatic, and lung tumors and bile duct carcinoma. In order to elucidate the role of ISL1 in breast cancer, we performed quantitative real-time polymerase chain reaction and Western blotting analysis, and we found that ISL1 was u...

journal_title：OncoTargets and therapy

authors： Li L,Sun F,Chen X,Zhang M

更新日期：2018-02-14 00:00:00

abstract：OBJECTIVE:This study aims to investigate the potential benefit of combination therapy with magnetic nanoparticles of Fe3O4 (Fe3O4-MNP) and gambogic acid (GA) on SMMC-7721 cells. METHODS:The inhibition of proliferation of SMMC-7721 cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assa...

journal_title：OncoTargets and therapy

authors： Tian L,Chen BA,Cheng J,Guo QL

更新日期：2015-08-26 00:00:00

abstract：Introduction:Forkhead box (FOX) superfamily members were recently shown to play important roles in tumor development and progression. Forkhead box S1 (FOXS1), a member of the FOX family, has been reported to be closely associated with malignant neoplasms. However, its expression and effect on hepatocellular carcinoma r...

journal_title：OncoTargets and therapy

authors： Lei D,Hu G,Chen Y,Hao T,Gao Y,Luo F

更新日期：2020-11-17 00:00:00

abstract：:Esophageal squamous cell carcinoma (ESCC) is often diagnosed at late incurable stage and lacks effective treatment strategy. Bufadienolides are cardiotonic steroids isolated from the skin and parotid venom glands of the toad Bufo bufo gargarizans Cantor with novel anticancer activity. However, there is little informat...

journal_title：OncoTargets and therapy

authors： Lv J,Lin S,Peng P,Cai C,Deng J,Wang M,Li X,Lin R,Lin Y,Fang A,Li Q

更新日期：2017-02-28 00:00:00

abstract：Purpose:The clinical studies carried out in the last few decades unequivocally introduced activated androgen receptor (AR) as a pathogenic feature of human malignancies which not only endows cancer cells with survival advantage, but also may be exploited for anticancer interventions. Patients and Methods:In this study...

journal_title：OncoTargets and therapy

authors： Soleymani Fard S,Yazdanbod M,Sotoudeh M,Bashash D,Mahmoodzadeh H,Saliminejad K,Mousavi SA,Ghaffari SH,Alimoghaddam K

更新日期：2020-10-02 00:00:00

abstract：Objective:Long non-coding RNA (lncRNA) ANRIL is emerging as a crucial role in ovarian cancer progression and prognosis. However, the precise molecular mechanism of ANRIL on ovarian cancer is not known. Thus, we aim to study the underlying mechanism of ANRIL on the action. Methods:The MTT assay assessed cell viability....

journal_title：OncoTargets and therapy

authors： Wang K,Hu YB,Zhao Y,Ye C

更新日期：2021-01-19 00:00:00

abstract：:Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibe...

journal_title：OncoTargets and therapy

authors： Yan Y,Grothey A

更新日期：2015-10-15 00:00:00